vantage mhealthcare inc (VNTH) Key Developments
Vantage Health Inc. has Changed its Name to Vantage mHealthcare, Inc
Jan 9 15
Vantage Health Inc. changed its name to Vantage mHealthcare, Inc.
Vantage mHealthcare, Inc. Amends Certificate of Incorporation and Adopts Amended and Restated Bylaws; Moves its Corporate Headquarters to New York
Jan 9 15
Vantage mHealthcare Inc. has amended its Certificate of Incorporation such that it is now a Delaware corporation and it increased its authorized shares outstanding from 250,000,000 to 500,000,000 shares and reclassified such capital stock into 450,000,000 shares of common stock, par value $0.001, and 50,000,000 shares of preferred stock, par value $0.001. The company has also adopted Amended and Restated Bylaws which, along with the amended Certificate of Incorporation, contain customary public company provisions.
The company has officially moved its corporate headquarters to New York, New York, while continuing operational headquarters in Mountain View, CA.
Vantage Health Inc. Provides Update on Scientific Developments
Nov 20 14
Vantage Health Inc. announced scientific updates. Over the last three months Vantage, and its parent company, has been developing version 2.0 of its sensor technology. Version 2.0 operates on a Bluetooth platform eliminating the need for physical connections to multiple smartphone platforms. The new sensor is wirelessly compatible with all devices that have Bluetooth capability and will also operate with tablet technology. Version 2.0 of the sensor has the capacity to be scaled up to 256 sensor channels. The molecular samples analyzed by the Vantage Sensor 2.0 were sent to a third party laboratory specializing in analytical, environmental and pharmacological testing. When testing for lower and higher concentrations of certain molecules, which are important biomarkers in disease detection, results suggested that the sensor may actually be more sensitive than Gas Chromatography--Mass Spectrometry (GC-MS). A GC-MS is considered the gold standard for molecular analysis typically costing as much as six figures. Vantage plans to retail this sensor for less than $200. A provisional patent was filed recently to protect the proprietary algorithm used to convert the nano-sensor data into useful calibrated measurements. The key inventor, formerly a NASA contractor, has been engaged to help imbed the algorithm into hand-held apps that communicate directly with the new Bluetooth device. The Company also recruited two additional staff members; a Chief Scientist for Nanotechnology who brings 10 years of experience and a Chief Technology Officer who brings 16 years of experience. The company and its partners have just completed version 3.0 of a breath capture device, which attaches directly onto the sensor. The breath capture device allows for unlimited use of the sensor without the risk of contamination between patients and also includes a filtering mechanism, removing water vapor in the breath, which could otherwise interfere with the molecular analysis. The parent company will be filing another provisional patent for this technology as well.
Vantage Health Inc. Auditor Raises 'Going Concern' Doubt
Oct 14 14
Vantage Health Inc. filed its 10-K on Oct 14, 2014 for the period ending Jun 30, 2014. In this report its auditor, Malone & Bailey, PLLC, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Vantage Health Inc. Appoints Tony Van Bijleveld as an Independent Member of Board of Directors
Sep 30 14
Vantage Health has appointed Tony van Bijleveld as an independent member of the Board of Directors of company. Van Bijleveld is currently General Manager with drug manufacturer Patheon/DPX. Over the past 30 years he has served in a variety of senior executive capacities in the pharmaceutical and biotech industry including: Managing Director of United Drug PLC, President/General Manager Russia for Schering Plough/MSD, SVP of Organon Biosciences, and Managing Director of KCL Foundation Labs.